Antibody-Drug Conjugates (ADCs) are a powerful class of therapeutic agents. These highly potent biological drugs are engineered by attaching a cytotoxic agent (payload) to an antibody using a chemical linker. Early efforts to develop ADCs resulted in setbacks due to toxicity, linker instability, and manufacturing issues. However, improvements in component bioconjugation and advances in linker technology have overcome many of those challenges. Consequently, a plethora of ADC approvals were granted in oncology in the last few years and nearly 100 investigational 3rd-generation ADCs are in preclinical and clinical development. Worldwide sales of currently marketed ADCs are forecast to exceed $16.4 billion in 2026. The global market for ADCs is expected to continue growing as novel agents enter the clinic across multiple oncology indications.
Oncology Resource Group (ONCrg) is a team of expert analysts who rigorously evaluate the latest corporate reports, news, and data presentations to distill out important advances in complex therapeutic areas. Our comprehensive medical congress coverage, and continuous market surveillance put these advances into the context of an overarching competitive landscape in ADCs to help guide strategic and tactical commercial development decisions for market participants.
